Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist.

ABSTRACT:

Background/objectives

Hypothalamic obesity (HO) frequently occurs following suprasellar tumors from a combination of decreased energy expenditure and increased energy intake. Glucagon-like peptide-1 receptor agonist (GLP1RA) therapy is associated with increased satiety and energy expenditure. We hypothesized GLP1RA therapy in patients with HO would cause both lower energy intake and increased energy expenditure.

Subjects/methods

Forty-two patients aged 10-26 years (median 16 years) with HO with suprasellar tumors were randomized to GLP1RA (exenatide extended release once-weekly, ExQW, n = 23) or placebo (n = 19). Thirty seven (81%) patients completed the 36-week double-blind placebo-controlled trial. Total energy expenditure (TEE) was measured with doubly labeled water, phys

SUBMITTER: Shoemaker AH 

PROVIDER: S-EPMC8881399 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature